Arkin Holdings
VC Fund
Herzliya, Israel
Arkin Holdings is a VC fund in Herzliya focused on Biotechnology and Health Care. Arkin Holdings is dedicated to empowering companies that create breakthrough pharma, biotech, medical device, and digital health technologies. Our synergistic healthcare investments are focused on creating innovations that benefit humanity and enhance medical care. We offer extensive experience, with a track record of successful healthcareinvestments. Experts in the dynamic world of healthcare development, we provide the know-how and close accompaniment that helps our portfolio investments achieve substantial value and growth. Arkin Holdings currently has a healthcare portfolio of $1.5 billion through its 5 investment arms. Its investors include a substantial amount of Israel’s top-tier institutional investors.
- Total investments:
- 32
- Last investment:
- Lead investor:
- 31%
- Fund size:
- $100M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Arkin Holdings invests in
Stages Arkin Holdings invests in
Countries Arkin Holdings invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $2M–$6M
- Series A
- $15M–$29M
- Series B
- $23M–$95M
Investment Focus
Industry
- Biotechnology 11 (34%)
- Health Care 7 (22%)
- Therapeutics 5 (16%)
- Medical 4 (13%)
- Life Science 4 (13%)
Stage
- Series A 7 (22%)
- Series B 6 (19%)
- Seed 5 (16%)
- Venture - Series Unknown 5 (16%)
- Series C 3 (9%)
Country
- Israel 14 (44%)
- United States 8 (25%)
- Switzerland 1 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Dan Goldstaub
Entrepreneur
|
Entrepreneur | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. We are leveraging our proprietary PREDATOR™ platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with thegoal of addressing the limitations of conventional proinflammatory immune therapies. Our INDUKINE™ molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Our most advanced product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2), and Interleukin-12 (IL-12) INDUKINE molecules for the treatment of solid tumors. | $150M / Post-IPO Equity / Aug 21, 2026 | ||
| Nocion Therapeutics is a developer of novel pharmaceuticals intended to treat the conditions arising from neurogenic inflammation. The company is developing "nocions" which are a new kind of therapy that selectively affects actively firing nociceptors, enabling patients to provide targeted, robust and sustained relief for the treatment ofserious conditions including cough, itch, pain and inflammation. | $23M / Series B / Jan 07, 2026 | ||
| Phytolon revolutionizes the way food colors are produce, by Leveraging a novel and sustainable technology for production of healthy food colors in high quality at low costs. Phytolon's mission is to exploit scientific advancement promote human health and environmental sustainability | Aug 13, 2025 | ||
| QuamCore is driving breakthroughs across industries by advancing the field of quantum computing, pushing the boundaries of what is possible, and bringing large-scale, commercially viable quantum computing to reality. | $26M / Series A / Aug 04, 2025 | ||
| Phytolon revolutionizes the way food colors are produce, by Leveraging a novel and sustainable technology for production of healthy food colors in high quality at low costs. Phytolon's mission is to exploit scientific advancement promote human health and environmental sustainability | Venture - Series Unknown / Nov 11, 2024 | ||
| Honeycomb (fka Agilius) is the only place where you can buy a condo/apartment building master policy online in less than 3 minutes at a fraction of the cost! Instant, free, no hassle quotes, online everything and up to 40% savings. With all that we're bringing simplicity and transparency to the real estate insurance space for condoassociations (HOAs), building owners, property managers, and developers everywhere. This is what we do. This is all we do. | $36M / Series B / May 07, 2024 | ||
| Nocion Therapeutics is a developer of novel pharmaceuticals intended to treat the conditions arising from neurogenic inflammation. The company is developing "nocions" which are a new kind of therapy that selectively affects actively firing nociceptors, enabling patients to provide targeted, robust and sustained relief for the treatment ofserious conditions including cough, itch, pain and inflammation. | $62M / Series B / Mar 04, 2024 | ||
| NextPoint Therapeutics develops medications to expand the benefit of immunotherapies to cancer patients. The company offers immunotherapies for a validated checkpoint axis that is independent of PD-1/L1 and modulates both adaptive and innate immune systems to find and destroy cancer cells. | $42.5M / Series B / Feb 14, 2024 | ||
| Human Immunology Biosciences is a biotechnology company that focuses on developing therapies for immune-mediated diseases. The company's lead product, felzartamab, is a fully human anti-CD38 monoclonal antibody that has been shown in clinical studies to deplete CD38+ cells that include plasma cells and natural killer, or NK, cells which mayallow for applications that improve clinical outcomes in a broad range of immune-mediated diseases. | $95M / Series B / Jan 04, 2024 | ||
| MadeRight offers a natural additive that enhances sustainable packaging. A natural additive fermented by fungi grown on industrial waste, serving as a performance enhancer for bio-plastics. It enables a scalable, affordable, and degradable additive to any plastic mix, improving the physical attributes and functional performance of the producedpackaging material, including anti-microbial and heat resistance. | $2M / Seed / Aug 24, 2023 | ||
| See all 32 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Arkin Holdings invest in?
Arkin Holdings invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 32 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Arkin Holdings's check size?
Arkin Holdings typically joins rounds of $2M–$6M at Seed, $15M–$29M at Series A and $23M–$95M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Arkin Holdings participates in.
How do I contact Arkin Holdings?
Public channels for Arkin Holdings include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Arkin Holdings?
The team at Arkin Holdings includes Dan Goldstaub (Entrepreneur). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
